Viron Therapeutics

Presenter: Kevin Sullivan, Vice President, Business Development

Company Information

Company Type: Pharmaceuticals

Development Stage: Private

Company Profile

Viron Therapeutics is a biopharmaceutical company pioneering the development of viral proteins, a revolutionary new class of drugs. By harnessing the evolutionary power of viruses and other pathogens to evade the human bodys protective inflammatory response, Viron is able to identify and develop powerful protein therapeutics that have distinct advantages in potency and efficacy over conventional drug therapy. The Companys proprietary PROSPECT technology, PROtein Screen for Pathogen-Evolved Combination Therapeutics, is a platform for the discovery of new immune-modulating protein therapeutics. Its significant pipeline of products target critical pathways that have broad application to immune and inflammatory-based diseases such as cardiovascular disease and rheumatoid arthritis. VT-111, the Companys lead compound, is in development to treat Acute Coronary Syndromes and solid organ transplant rejection.

Presenter Bio

Kevin Sullivan
Vice President, Business Development
Mr. Sullivan has over 10 years experience with early stage biotechnology companies. Since joining Viron in 2003, Mr. Sullivan has advanced partnering discussions with prospective pharmaceutical companies and participated in raising over $30 million in private equity and non dilutive government funding. His background in immunology and business builds the bridge between the business and science interests of the company. Before joining Viron, Mr. Sullivan worked in the field of molecular diagnostics for the environmental and food safety industry. Mr. Sullivan holds an MBA from the Richard Ivey School of Business and received an Honours degree in Immunology from Dalhousie.

Contact

Viron Therapeutics
700 Collip Circle, Suite 203
London
Ontario, Canada
N6G 4X8

ph: (519) 858-5109
fx: (519) 858-5103

www.vironinc.com
ksullivan@vironinc.com